Things I Did Today

Here are today’s things:

* I added to $MSOS at $4.22 and $GLAS at $4.25 longs.

*I added to $PEP long at $125.87.

* I am reshorting $GRNY at $28.43.

* I added to my $NVDA short at $232.98.

Position: Long MSOS common (VL) and calls (S), PEP (M); Short GRNY (M), NVDA (S)

GRNY, PEP Moves

I added back to my $GRNY short at $28.43.

Selling on a scale higher.

I added to my $PEP long at $125.58.

Positions: Long PEP M, Short GRNY VS

Pepsi Tastes Even Better

We aggressively purchased $PEP in the premarket on Thursday and in early trading in the regular session.

Pepsico’s shares rose by over +$4 yesterday follwing the EPS and Sales guidedown.

Here is a summary of Goldman Sachs’ view of the company:

While investors debate whether PEP can grow earnings next year, we take a more optimistic view and expect faster topline growth on both the top and bottom lines albeit likely below the company’s l.t. growth algo. As such, we continue to see a positive risk-reward profile on the stock, especially as we think positioning and sentiment skews overly negative. Further, we think PEP’s valuation is attractive – with the stock trading at a very sharp discount (~10x) on a forward P/E basis relative to KO on a forward P/E basis – well below it’s l.t. historical average discount of ~1x – while also trading at a ~5x discount to PG (i.e., a Staples peer) despite a similar topline growth profile (to PG).

Bottom Line – We maintain our Buy rating on PEP, as we believe it remains well positioned given its strong brand portfolio and long-term growth opportunities in both

Food & Beverages, particularly given a robust innovation pipeline, its impressive revenue growth management capabilities, its owned distribution network and superior supply chain, which ensures the right (& affordable) products are available when & where needed. Overall, we believe PEP should be able to deliver sustainable average annual +MSD organic sales growth in the next decade – despite some near-term headwinds.

 Piper On PEP

Piper Sandler lowered the firm’s price target on PepsiCo to $140 from $176 and keeps an Overweight rating on the shares. Despite a Q3 EPS beat, driven by strong International momentum, PEP faces growing input cost pressure and weak U.S. trends. Further brand spend increases are coming, also weighing on margins. It has a decent innovation pipeline for 2027, focused on functional benefits, like protein and hydration, but sustainable better growth is still unproven, argues Piper.

BofA on PEP 

BofA analyst Peter Galbo lowered the firm’s price target on PepsiCo to $145 from $152 and keeps a Neutral rating on the shares. The company’s Q3 beat came with better than feared Pepsi Foods NA organic sales and commentary on sequential organic revenue acceleration into Q4, but a lowered fiscal year earnings outlook signals ongoing cost challenges and raises questions around the ability to grow EPS in FY27, the analyst tells investors.

Positions: Long PEP M

Things I Did Today

Here are today’s things:

* I covered all of my Index shorts: $SPY $772.55 and $QQQ $751.41 (for a quick profit from last night).

* I am back buying $PEP at $124.88

* I added to $MSOS $4.39, $GTBIF $6.61 and $GLAS $4.99

* I added to $GRNY short at $28.49.

Long MSOS common VL calls VS GTBIF S GLAS S PEP M

Short GRNY M

Upside, Downside Movers in the Morning

Upside

– $PROF +19% (preliminary Q3 revenue was about 45%-47% above consensus, with gross margin expected above 70%)

– $HAE +14% (no fresh company catalyst confirmed; unusually large move on light premarket volume)

– $WOLF +13% (received a conditional commitment for up to $1.5B of 30-year U.S. defense financing, partly offset by warrants for up to 7.5% of diluted equity)

– $EFX +4.5% (no fresh company catalyst confirmed; unusually large premarket move)

– $APA +3.1%, OXY +2.5%, DVN +2.4% (oil producers rise as WTI and Brent jump roughly 4.5%)

– $PLTR +2.3% (extends AI-software momentum despite weaker index futures)

– $PEP +1.6% (Q3 revenue and profit beat expectations; a better-than-feared quarter offsets a cut to the FY earnings-growth outlook)

Downside

– $ARGX -15% (Phase 3 UNITY study in Sjögren’s disease was stopped for futility, overshadowing positive Phase 2 celiac-disease data)

– $GLW -3.3% (no fresh company catalyst confirmed; unusually large premarket move)

– $EQIX -3.0% (rate-sensitive data-center REIT falls as the 10-year Treasury yield climbs to roughly 5.33%)

– $NXPI -3.1%, $AMAT -2.5%, $LRCX -2.9%, $HPE -2.0% (semiconductor and hardware names weaken as Treasury yields rise and global technology shares sell off)

– $SHW -2.7% (crude-oil surge raises petrochemical feedstock and input-cost concerns)